CTLA4 and cancer: This strategy, which prevents Treg reduction and ensures strong CTLA-4 inhibition in the TME, seeks to optimize the pivotal functions of these immune checkpoints in cancer immunotherapy, potentially yielding enhanced therapeutic benefits while minimizing adverse effects relative to conventional antibody treatments [136].